ARGX Q4 2024 Earnings — argenx SE Revenue & Financial Results | Market Cap Arena

ARGXargenx SE

$46B

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1.3B+77.7% YoY

Gross Profit

$681M50.6% margin

Operating Income

$117M8.7% margin

Net Income

$866M64.3% margin

EPS (Diluted)

$12.20

QoQ Revenue Growth

+134.9%

Cash Flow

Operating Cash Flow

$42M

Free Cash Flow

$41M

Stock-Based Comp.

$128M

Balance Sheet

Total Assets

$6.2B

Total Liabilities

$704M

Stockholders' Equity

$5.5B

Cash & Equivalents

$1.5B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1.3B	$758M	+77.7%
Gross Profit	$681M	$184M	+270.2%
Operating Income	$117M	-$219M	+153.5%
Net Income	$866M	-$156M	+656.2%